CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The grants are expected to be received over the next three years, commencing March 2022
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The facility will cater to the storage, handling and transportation of pharma, dairy products seafood among others
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Subscribe To Our Newsletter & Stay Updated
